NCT02445794View on ClinicalTrials.gov

A First in Human Study of RT001 in Patients With Friedreich's Ataxia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

July 31, 2016

Conditions
Friedreich's Ataxia
Interventions
DRUG

Low dose cohort

RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.

DRUG

High dose cohort

RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.

Trial Locations (2)

33612

University of South Florida, Tampa

90806

Collaborative Neuroscience Network, LLC, Long Beach

All Listed Sponsors
lead

Biojiva LLC

INDUSTRY

NCT02445794 - A First in Human Study of RT001 in Patients With Friedreich's Ataxia | Biotech Hunter | Biotech Hunter